TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15547521

Group type: EXPERIMENTAL
Intervention: Vaginal prolapse and incontinence surgery
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Age <60 years
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Preoperative pelvic organ prolapse quantification stage III or IV
Number of subjects: 176
Study: 11251138

Group type: EXPERIMENTAL
Intervention: 20-gauge Tuohy needle with loss-of-resistance (LOR) technique
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fluoroscopy confirmation
Number of subjects: 100
Study: 10233493

Group type: EXPERIMENTAL
Intervention: VIP/P-1 (25 micrograms VIP combined with 1.0 mg PM)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: VIP/P-2 (25 micrograms VIP combined with 2.0 mg PM)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study: 7697277

Group type: EXPERIMENTAL
Intervention: Heat and moisture exchanger (Group 1)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Heated humidifier (Group 2)
Number of subjects: 131
Study: 2774267

Group type: EXPERIMENTAL
Intervention: Ohio anesthesia ventilator, N2O/O2
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ohio anesthesia ventilator, N2/O2
Number of subjects: 54

Group type: COMPARATOR
Intervention: Siemens ventilator (groups 1 and 2)
Number of subjects: 54
Study: 353721

Group type: EXPERIMENTAL
Intervention: Nomifensine, 4 capsules daily for 4 weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Nortriptyline, 4 capsules daily for 4 weeks
Number of subjects: 65
Study: 31718332

Group type: EXPERIMENTAL
Intervention: Epi-no® device, inflated within the vagina to measure maximum circumference
Number of subjects: 32
Study: 31278694

Group type: EXPERIMENTAL
Intervention: Morphine ARER 100 mg under fed conditions
Number of subjects: 28

Group type: COMPARATOR
Intervention: Morphine ARER 100 mg under fasted conditions
Number of subjects: 28
Study: 28557548

Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride extended-release chewable tablets (MPH ERCT) at 20-60 mg/day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride extended-release chewable tablets (MPH ERCT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 26559364

Group type: EXPERIMENTAL
Intervention: Wet-cupping (hijama) in addition to conventional hypertension treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional hypertension treatment only
Number of subjects: 80
Study: 23583166

Group type: EXPERIMENTAL
Intervention: Diabetic retinopathy screening with a small copayment
Number of subjects: 2766

Group type: COMPARATOR
Intervention: Free access to diabetic retinopathy screening
Number of subjects: 2766
Study: 22413378

Group type: EXPERIMENTAL
Intervention: Federally funded family finding project
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard child welfare services
Number of subjects: 0
Study: 20139574

Group type: EXPERIMENTAL
Intervention: Calcium phosphate cement (CPC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite ceramic granules (HAG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (debridement alone)
Number of subjects: 60
Study: 16927385

Group type: EXPERIMENTAL
Intervention: Short and long term family therapy
Number of subjects: 0
Study: 15567633

Group type: EXPERIMENTAL
Intervention: Hand delivery of questionnaires
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: Long questionnaire (14 pages)
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: Short questionnaire (8 pages)
Number of subjects: 802

Group type: COMPARATOR
Intervention: Post delivery of questionnaires
Number of subjects: 802
Study: 11395233

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy for tumors with low proliferation
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy for tumors with high proliferation
Number of subjects: 152

Group type: COMPARATOR
Intervention: Surgery alone (control group)
Number of subjects: 152
Study: 9432453

Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted pelvic floor muscle training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prompted voiding program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate treatment group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed treatment group (control)
Number of subjects: 0
Study: 9499549

Group type: EXPERIMENTAL
Intervention: 10 mg medrogeston for six cycles
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 10 mg dydrogesteron for six cycles
Number of subjects: 31
Study: 2677376

Group type: EXPERIMENTAL
Intervention: Trimazosin (50‐200 mg twice daily)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Propranolol (40‐160 mg twice daily)
Number of subjects: 22
Study: 1108350

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulphamethoxazole, 2 tablets twice a day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ampicillin, 500 mg four times a day
Number of subjects: 30
Study: 30862174

Group type: EXPERIMENTAL
Intervention: Active audiovisual stimulation (AVS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo-control audiovisual stimulation (AVS)
Number of subjects: 16
Study: 29045745

Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 26094857

Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonist exenatide
Number of subjects: 48

Group type: COMPARATOR
Intervention: GLP-1 receptor blockade by exendin-9-39
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 23475594

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 386

Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 386
Study: 22125984

Group type: EXPERIMENTAL
Intervention: 2% Lignocaine with 1:100,000 epinephrine dental local anaesthetic
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (normotensive patients)
Number of subjects: 60
Study: 19632976

Group type: EXPERIMENTAL
Intervention: Quit Smoking Network (QSN) treatment program
Number of subjects: 1028

Group type: COMPARATOR
Intervention: Active Lives control condition
Number of subjects: 1028

Group type: EXPERIMENTAL
Intervention: Non-assigned treatments (various types)
Number of subjects: 1028
Study: 16555159

Group type: EXPERIMENTAL
Intervention: RET proto-oncogene polymorphisms (exon2) in HD patients
Number of subjects: 94

Group type: COMPARATOR
Intervention: RET proto-oncogene polymorphisms (exon2) in control subjects
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: RET proto-oncogene polymorphisms (exon13) in HD patients
Number of subjects: 94

Group type: COMPARATOR
Intervention: RET proto-oncogene polymorphisms (exon13) in control subjects
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: RET proto-oncogene polymorphisms (exon11) in HD patients
Number of subjects: 94

Group type: COMPARATOR
Intervention: RET proto-oncogene polymorphisms (exon11) in control subjects
Number of subjects: 94

Group type: COMPARATOR
Intervention: RET proto-oncogene polymorphisms (exon15) in both HD patients and control subjects
Number of subjects: 94
Study: 14964520

Group type: EXPERIMENTAL
Intervention: Psychoeducational group intervention
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (nontreatment)
Number of subjects: 58
Study: 11381720

Group type: EXPERIMENTAL
Intervention: Supplemental decision-support materials to inform consumers about expected health plan costs
Number of subjects: 0

Group type: COMPARATOR
Intervention: No supplemental decision-support materials
Number of subjects: 0
Study: 9409050

Group type: EXPERIMENTAL
Intervention: Ibuprofen (200 mg tablets, two tablets administered pre-operatively)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo (two matching placebo tablets administered pre-operatively)
Number of subjects: 127
Study: 8287650

Group type: EXPERIMENTAL
Intervention: 5-hydroxy-L-tryptophan
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: gamma-L-glutamyl-5-hydroxy-L-tryptophan
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 3518771

Group type: EXPERIMENTAL
Intervention: Slow release nifedipine 40 mg at 1 and 12 h
Number of subjects: 20

Group type: COMPARATOR
Intervention: Atenolol 100 mg at 0 h
Number of subjects: 20
Study: 31648851

Group type: EXPERIMENTAL
Intervention: Vinflunine/gemcitabine (VG)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Carboplatin/gemcitabine (CG)
Number of subjects: 62
Study: 29185089

Group type: EXPERIMENTAL
Intervention: Micafungin (€4422)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Caspofungin (€2693)
Number of subjects: 0
Study: 26682647

Group type: EXPERIMENTAL
Intervention: Telephone Call group
Number of subjects: 75

Group type: COMPARATOR
Intervention: No Telephone Call group
Number of subjects: 75
Study: 24687145

Group type: EXPERIMENTAL
Intervention: Pneumatic trabecular bypass (PTB)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Trabeculotomy (T)
Number of subjects: 42
Study: 22324297

Group type: EXPERIMENTAL
Intervention: GlideScope videolaryngoscope
Number of subjects: 60

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 60
Study: 20519807

Group type: EXPERIMENTAL
Intervention: Miglitol administered just before a meal (50 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Miglitol administered at 30 min after the start of a meal (50 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 0
Study: 18535017

Group type: EXPERIMENTAL
Intervention: rs6983267 variant
Number of subjects: 2587

Group type: EXPERIMENTAL
Intervention: Regional haplotype containing rs10808555, rs6983267 and rs7837328
Number of subjects: 2587
Study: 16435699

Group type: EXPERIMENTAL
Intervention: Spoken prompts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual prompts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Difficult tracking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tracking performance
Number of subjects: 0
Study: 12907008

Group type: EXPERIMENTAL
Intervention: PnCRM7 vaccine
Number of subjects: 8292

Group type: COMPARATOR
Intervention: MnCC control vaccine
Number of subjects: 8292
Study: 10566919

Group type: EXPERIMENTAL
Intervention: Ametop
Number of subjects: 32

Group type: COMPARATOR
Intervention: EMLA
Number of subjects: 32
Study: 8737229

Group type: EXPERIMENTAL
Intervention: r‐HuEpo (200 U, subcutaneously administered, three times weekly for 4 weeks)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: r‐HuEpo
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1832972

Group type: EXPERIMENTAL
Intervention: Clomipramine (CMI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7055169

Group type: EXPERIMENTAL
Intervention: Laminaria treatment (n = 45)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control (n = 26)
Number of subjects: 71
Study: 30783732

Group type: EXPERIMENTAL
Intervention: Mometasone (inhaled)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 29885896

Group type: EXPERIMENTAL
Intervention: Short feeding duration with DCAD of -70 mEq/kg of DM (n = 29)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Short feeding duration with DCAD of -180 mEq/kg of DM (n = 29)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Long feeding duration with DCAD of -70 mEq/kg of DM (n = 28)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Long feeding duration with DCAD of -180 mEq/kg of DM (n = 28)
Number of subjects: 116

Group type: COMPARATOR
Intervention: DCAD -70 mEq/kg of DM
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: DCAD -180 mEq/kg of DM
Number of subjects: 116

Group type: COMPARATOR
Intervention: Short feeding duration (21 d)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Long feeding duration (42 d)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: DCAD reduction from -70 to -180 mEq/kg of DM
Number of subjects: 116
Study: 26707619

Group type: EXPERIMENTAL
Intervention: 50,000 IU/wk vitamin D3 (cholecalciferol)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: 5000 IU/d vitamin D3 (cholecalciferol)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: 1000 IU/d vitamin D3 (cholecalciferol)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Obese participants
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Hispanic participants
Number of subjects: 183
Study: 24436294

Group type: EXPERIMENTAL
Intervention: Effective stimulation (ES) - skin pressure stimulation at the hallux tip and first metatarsal joint (0.58 ± 0.04 kg/mm(2))
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham stimulation (SS)
Number of subjects: 16
Study: 22888833

Group type: EXPERIMENTAL
Intervention: Worksite aerobic exercise (60 min per week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference group receiving lectures concerning healthy living
Number of subjects: 0
Study: 18401648

Group type: EXPERIMENTAL
Intervention: Virtual-reality (VR) training environment for bimanual carrying (BC) task
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Virtual-reality (VR) training environment for needle passing (NP) task
Number of subjects: 8

Group type: COMPARATOR
Intervention: Actual training environment for needle passing (NP) task
Number of subjects: 8
Study: 17580534

Group type: EXPERIMENTAL
Intervention: Insulin glargine once daily (n = 18)
Number of subjects: 48

Group type: COMPARATOR
Intervention: NPH insulin twice daily (n = 15)
Number of subjects: 48

Group type: COMPARATOR
Intervention: NPH insulin once daily at bedtime with more intensive self-monitoring (n = 15)
Number of subjects: 48
Study: 15590586

Group type: EXPERIMENTAL
Intervention: Beta-carotene (50 mg on alternate days)
Number of subjects: 39876

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39876
Study: 11576104

Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 20% end‐expired
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 40% end‐expired
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 60% end‐expired
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (all concentrations)
Number of subjects: 20
Study: 9672774

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg o.d. for 10 days)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 7720799

Group type: EXPERIMENTAL
Intervention: Heliosit
Number of subjects: 37

Group type: COMPARATOR
Intervention: Concise
Number of subjects: 37
Study: 2573918

Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1041620

Group type: EXPERIMENTAL
Intervention: Experimental group (simulation gaming)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 30783776

Group type: EXPERIMENTAL
Intervention: Collagen peptides (CP) 20 g day−1
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo control (CON)
Number of subjects: 24
Study: 29161454

Group type: EXPERIMENTAL
Intervention: Native-specific independent spiritual practices
Number of subjects: 134

Group type: COMPARATOR
Intervention: Non-AI/AN participants
Number of subjects: 134
Study: 26867337

Group type: EXPERIMENTAL
Intervention: Thymosin therapy (1.6 mg subcutaneous injection, qd X 7 d)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Routine therapy (ICU conventional treatment)
Number of subjects: 52
Study: 22763798

Group type: EXPERIMENTAL
Intervention: L-arginine supplementation (7 g/day for 1 week)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (matched healthy controls)
Number of subjects: 10
Study: 21971663

Group type: EXPERIMENTAL
Intervention: L‐Ala‐Gln 20% plus saline 750 ml (Group L‐Ala‐Gln, n=11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Saline 1000 ml (Group Saline, n=11)
Number of subjects: 22
Study: 17512527

Group type: EXPERIMENTAL
Intervention: Breastfeeding empowerment programme (4 sessions of 60 minutes each for 4 weeks)
Number of subjects: 60
Study: 16709595

Group type: EXPERIMENTAL
Intervention: Diuretic use
Number of subjects: 1391

Group type: COMPARATOR
Intervention: No diuretic use
Number of subjects: 1391
Study: 15508179

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT) with birch pollen extract
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with birch pollen extract
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 11430776

Group type: EXPERIMENTAL
Intervention: Energy restriction (‐2929 kJ/d) and drug therapy (or placebo)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Energy restriction (‐2929 kJ/d)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Post-programme weight stability
Number of subjects: 35
Study: 9153530

Group type: EXPERIMENTAL
Intervention: Interferon beta-1b
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (patients prior to treatment)
Number of subjects: 0
Study: 7974898

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colony-stimulating factor support for chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjunctive surgical therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newer cytotoxic regimens
Number of subjects: 0
Study: 2455188

Group type: EXPERIMENTAL
Intervention: Transdermal clonidine (TC)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Oral propranolol (OP)
Number of subjects: 32
Study: 30677198

Group type: EXPERIMENTAL
Intervention: Peer support group (telephone-based peer support)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Usual care group (routine care and health education measures)
Number of subjects: 76
Study: 27693054

Group type: EXPERIMENTAL
Intervention: Posterior cruciate ligament substituting (PS) total knee arthroplasty
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Posterior cruciate ligament retaining (CR) total knee arthroplasty
Number of subjects: 100

Group type: COMPARATOR
Intervention: Both groups (PS and CR)
Number of subjects: 100
Study: 25720615

Group type: EXPERIMENTAL
Intervention: Lactobacillus brevis CD2 lozenges, three times daily for 14 days
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo, three times daily for 14 days
Number of subjects: 34
Study: 23877055

Group type: EXPERIMENTAL
Intervention: PortionSize@warenessTool (intervention group)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 310
Study: 20512394

Group type: EXPERIMENTAL
Intervention: EPO group A (n = 13)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EPO group B (n = 14)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (n = 25)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EPO group A
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EPO group B
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EPO groups (A and B combined)
Number of subjects: 40
Study: 18499176

Group type: EXPERIMENTAL
Intervention: Microsurgical varicocelectomy
Number of subjects: 298

Group type: COMPARATOR
Intervention: Open varicocelectomy
Number of subjects: 298

Group type: COMPARATOR
Intervention: Laparoscopic varicocelectomy
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: All groups (Microsurgical, Open, Laparoscopic)
Number of subjects: 298
Study: 16600170

Group type: EXPERIMENTAL
Intervention: Midbrain DNA from PD cases
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Caudate nucleus/putamen DNA from PD cases
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Thalamus DNA from PD cases
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Hippocampus DNA from PD cases
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: DNA conformation in midbrain, caudate nucleus/putamen, thalamus, and hippocampus in PD
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Frontal, temporal, and occipital cortex, and cerebellum DNA from PD cases
Number of subjects: 11
Study: 14561542

Group type: EXPERIMENTAL
Intervention: 1% propofol
Number of subjects: 400
Study: 10811265

Group type: EXPERIMENTAL
Intervention: Calcium pentosan polysulphate (CaPPS) 10 mg/kg orally, once weekly for four weeks, repeated every 12 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium pentosan polysulphate (CaPPS)
Number of subjects: 0
Study: 8781669

Group type: EXPERIMENTAL
Intervention: L-ASA (90 mg/ml)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (glycine solution 30 mg/ml)
Number of subjects: 16
Study: 1616392

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Amodiaquine (AM)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Quinine (QN)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (S-P)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Mefloquine 15 mg kg-1 (M15)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Mefloquine 25 mg kg-1 (M25)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) treatment failures treated with Mefloquine 25 mg kg-1
Number of subjects: 325
Study: 6549515

Group type: COMPARATOR
Intervention: Argon laser iridotomy
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser iridotomy
Number of subjects: 21
Study: 31146656

Group type: EXPERIMENTAL
Intervention: Hepatitis C patients (mean Tacstd-2 concentration 691.2 ± 473.3 ng/U)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Healthy control group (mean Tacstd-2 concentration 524 ± 290.1 ng/U)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Cirrhotic hepatitis C patients
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Hepatitis C patients with Tacstd-2 <500 ng/U
Number of subjects: 61
Study: 29171829

Group type: EXPERIMENTAL
Intervention: Decision aid used at academic clinic
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Decision aid used at community clinic
Number of subjects: 242

Group type: COMPARATOR
Intervention: Decision aid
Number of subjects: 242
Study: 28283148

Group type: EXPERIMENTAL
Intervention: Mobile phone with access to the MOTECH Suite application and a closed user group
Number of subjects: 327

Group type: COMPARATOR
Intervention: Mobile phone set up on a closed user group but with no application
Number of subjects: 327

Group type: COMPARATOR
Intervention: No mobile phone but same level of training as the previous 2 groups
Number of subjects: 327